Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Vaccinia-Complication Draft Guidance Emphasizes Data Collection Systems

This article was originally published in The Pink Sheet Daily

Executive Summary

The second of three guidances on FDA's counter-terrorism plans strongly encourages early communication with the agency. Guidance on smallpox drug development is forthcoming.

You may also be interested in...



Bavarian Nordic Smallpox Vaccine Is Imvamune; U.S. Trials To Commence This Year

The company expects to begin large-scale production by mid-2005 and plans to seek a U.S. commercialization partner for the third-generation smallpox vaccine.

Bavarian Nordic Smallpox Vaccine Is Imvamune; U.S. Trials To Commence This Year

The company expects to begin large-scale production by mid-2005 and plans to seek a U.S. commercialization partner for the third-generation smallpox vaccine.

Biodefense R&D: First Anthrax Vaccine Could Enter Phase II In 2004

An HHS contract is supporting the development of VaxGen's recombinant anthrax vaccine. Acambis/Baxter's second-generation smallpox vaccine ACAM-2000 is in Phase II.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel